Aptorum Group Ltd Class A (APM) - Total Liabilities
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has total liabilities worth $4.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Aptorum Group Ltd Class A to assess how effectively this company generates cash.
Aptorum Group Ltd Class A - Total Liabilities Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Check APM asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Aptorum Group Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Aptorum Group Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hydrofarm Holdings Group Inc
NASDAQ:HYFM
|
USA | $191.40 Million |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
USA | $33.96K |
|
Bang Overseas Limited
NSE:BANG
|
India | Rs1.03 Billion |
|
Vivesto AB
ST:VIVE
|
Sweden | Skr16.44 Million |
|
JPMorgan Indian Inv Trust
LSE:JII
|
UK | GBX24.00 Million |
|
Masivo Silver Corp
V:MASS
|
Canada | CA$479.21K |
|
Destiny Media Technologies Inc
V:DSY
|
Canada | CA$496.86K |
|
Mitra International Resources
JK:MIRA
|
Indonesia | Rp87.64 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Aptorum Group Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aptorum Group Ltd Class A stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptorum Group Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual total liabilities of Aptorum Group Ltd Class A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.90 Million | +12.56% |
| 2024-12-31 | $4.35 Million | -17.19% |
| 2023-12-31 | $5.26 Million | -59.67% |
| 2022-12-31 | $13.03 Million | +196.15% |
| 2021-12-31 | $4.40 Million | -27.60% |
| 2020-12-31 | $6.08 Million | -33.22% |
| 2019-12-31 | $9.10 Million | -26.17% |
| 2018-12-31 | $12.33 Million | +826.46% |
| 2017-12-31 | $1.33 Million | +393.16% |
| 2016-12-31 | $269.84K | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more